Latest News
Getting Away From the Guilt Trip: Reflections on Balancing Family Life with Our Livelihood
In response to December's episode of the HOPA Now Podcast, HOPA Wellness Advisory Group member Teresa Kam Thakrar contributed the following personal reflection about balancing family with a career in oncology pharmacy.
Late-Breaking HOPA News: Belantamab Mafodotin-bmlf Returns: FDA Restores BCMA-Targeted ADC Option for RRMM
Marshall Winget, PharmD, and Bradley Yelvington, PharmD, BCOP, discuss the recent reapproval of belantamab mafodotin in BCMA-directed therapy for relapsed or refractory multiple myeloma.
Pharmacist's Application to Practice: Linvoseltamab-gcpt
Nikki Kalem, PharmD, PGY2 Oncology Pharmacy Resident, at Henry Ford Hospital in Detroit, MI, writes about the recent accelerated approval of linvoseltamab-gcpt for the treatment of relapsed or refractory multiple myeloma in adults.
Late-Breaking HOPA News: The Evolving Landscape of NPM1-Mutated AML
Moh'd Mohanad A. Al-Dabet, PhD, AHI(AMT); Katia Al-Sawalha, BSc; and Olivia White, PharmD, BCOP, review revumenib and ziftomenib for NPM-1m disease and highlight key considerations when implementing these two therapies.
What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown
On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.
HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity
ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.
Explore more from HOPA
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
